U.S. government buys out Redsewein supply in next 3 months

Introduction: In the next three months, the UK, the EU and other countries will not be able to buy Insiewe, or face the embarrassment of being almost "drug-free"compiledthe foreign media pharmaphorum.com recently reported that the U.Sgovernment has reached a procurement agreement with Gilead Science to buy out almost all of Redsewe's supply in the next three monthsThis means that for at least the next three months, the UK, the EU and other countries will not be able to buy Ridsewe, or face the embarrassment of being almost "drug-free"U.SDepartment of Health and Human Services (HHS) Secretary Alex Azar said in a statement that U.SPresident Donald Trump and Gilead Sciences reached a "very great" agreement that secured the vast majority of Redseve's global supply to ensure Americans get the first approved drug for the new coronapneumoniareported that the Trump administration has purchased more than half a million courses of Redsewe for U.Shospitals, enough to last until the end of SeptemberHalf a million courses of treatment, equivalent to Gilead's total production in July (about 942,000 sessions) and 90 percent of all production in August and SeptemberIn August and September, Gilead will supply 174,900 and 232,800 courses to the U.Sgovernment, respectivelyU.Shospitals will receive the drugs from wholesaler Amerisource Bergen and will pay a wholesale price of $3,200 for a course of $520 per course (five days and six doses) recently announced by Gilead for a private insurance companyin clinical trial results released at the end of April, HHS has allocated 1.5 million doses donated by Gilead in the early stages of the outbreak, after Redsewe showed its effectiveness in COVID-19 for the first timeHHS said the agency will continue to distribute the drug to states and territories under the COVID-19 hospital burden The purchased Redseve deliveries will be simplified and sent directly to the hospital, rather than going to the state health department for subsequent delivery COVID-19 is a global pandemic, with more than 10.8 million confirmed cases and more than 510,000 deaths Redsivir is an antiviral drug that has been granted emergency use authorizations in several countries for the treatment of critically ill patients in May, Gilead signed a non-exclusive voluntary licensing agreement with five generic pharmaceutical companies in India and Pakistan to supply Redsivir generics to 127 countries around the world, covering almost all low- and middle-income countries However, these Redseve generics cannot be sold to the UK, EU and other markets because of Gilead's patents while the Trump administration has pursued a "America First" policy in acquiring Redseywe On Twitter, the U.S government's bid to buy out Future Reedsewe's supply has also sparked strong opposition from people in other countries Dr Andrew Hill, senior visiting researcher at the University of Liverpool, said: "There must be equality between countries In return, British patients who took part in clinical trials that proved Redsewe effective should have access to Redsewe , however, it has also been pointed out that the generic steroid drug dexamethasone may be a cheaper and more effective alternative Results from large-scale randomized clinical trials from RECOVERY controlled in the UK showed that low-dose dexamethast in patients with critical coVID-19 had reduced mortality by 35 per cent compared to standard care, which has not been observed in other clinical trials published to date Source: US government buys of the world's supply of COVID-19 drug remdesivir